Alexandra Shimmings
Executive Editor, Europe at Scrip
Executive Editor, Europe at The Pink Sheet
Executive Editor, Europe at In Vivo
Executive Editor (R&D, Commercial) for Scrip, Pink Sheet and In Vivo. Work brain interested in pharma and biotech R&D. Tweets are my own, not Norstella's.
Articles
-
2 weeks ago |
insights.citeline.com | Alexandra Shimmings
Pipeline Growth Slowed In 2024 But Oncology And Neurologicals Held StrongThere was a reduction in the rate of expansion of the pharma pipeline last year but 2024 also saw another welcome increase in the number of drug candidates in Phase III following years of stagnation.
-
2 weeks ago |
insights.citeline.com | Alexandra Shimmings
Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings07 Apr 2025There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.Choppy stock performance could make further biopharma IPOs difficult in 2025 (Shutterstock)
-
3 weeks ago |
insights.citeline.com | Alexandra Shimmings
Orphans Cling On To Growth Advantage As Market Share Heads Towards 20%It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
-
1 month ago |
insights.citeline.com | Alexandra Shimmings
Cassava At Crossroads As Simufilam Finally Exits, Stage LeftThe Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
-
1 month ago |
insights.citeline.com | Alexandra Shimmings
No Ace For J&J’s VENTURA Studies Of Aticaprant In Depression The future of kappa opioid receptor antagonism as a therapeutic strategy in major depressive disorder is looking increasingly bleak after J&J dropped aticaprant from development, but rival Neumora is pressing on with navacaprant.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 1K
- DMs Open
- No
RT @ScripMandy: Companies such as $BMY noted in recent Q2 earnings calls that they felt confident they could manage discounts provided to M…
Very sad news. Condolences to his family, and all who knew and worked with him.
We are deeply saddened by the news that José Baselga, EVP Oncology R&D, has passed away. An outstanding scientific leader, José leaves a lasting legacy in the scientific community and here at AstraZeneca. We send our condolences to his family. https://t.co/hiVTYIkdKm https://t.co/l8KbwnHujg
RT @owentg: Just gone to tell Edward Jenner the good news. https://t.co/6GOg1vAOtc
